Phathom’s First Approval Of Voquezna Expected To Lay Ground For Larger Indications

The Takeda spinout got FDA approval of its acid blocker as combination therapy for H. pylori infections, but the bigger opportunities await in erosive esophagitis and non-erosive reflux disorder.